Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Hedyeh Ebrahimi, Nazlı Dizman, Luís Meza, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2576-2585
Open Access | Times Cited: 24

Showing 24 citing articles:

AXL: shapers of tumor progression and immunosuppressive microenvironments
Yihui Liu, Lei Xu, Yuanyao Dou, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
The gut microbiome and cancer response to immune checkpoint inhibitors
Francesca S. Gazzaniga, Dennis L. Kasper
Journal of Clinical Investigation (2025) Vol. 135, Iss. 3
Open Access | Times Cited: 2
The role of microbial indole metabolites in tumor
Dingjiacheng Jia, Zheng Kuang, Liangjing Wang
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 1
Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy
Maruhen Amir Datsch Silveira, Richard R. Rodrigues, Giorgio Trinchieri
Gastroenterology Clinics of North America (2025)
Closed Access
Encouraging co-targeting of immunoregulatory molecules in cancer treatment
Takumi Sato, Yu Fujiwara
Immunotherapy (2025), pp. 1-4
Closed Access
An update and overview of the various health‐related benefits of probiotics: A focus on clinical trials demonstrating efficacy, tolerability and use in patients with impaired glucose tolerance and type 2 diabetes
Takayuki Toshimitsu, Junichiro Irie
Diabetes Obesity and Metabolism (2025) Vol. 27, Iss. S1, pp. 15-22
Open Access
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma
Vinay K. Giri, Jacob Zaemes
Expert Review of Anticancer Therapy (2025)
Closed Access
Overview on biomarkers for immune oncology drugs
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
Assessing the impact of probiotics on immunotherapy effectiveness and antibiotic-mediated resistance in cancer: a systematic review and meta-analysis
Shuya Zhao, Zhenzhou Lü, Fangmin Zhao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Unlocking the power of the microbiome for successful cancer immunotherapy
Maria Alejandra Clavijo-Salomon, Giorgio Trinchieri
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e011281-e011281
Open Access
Immunotherapy for Renal Cell Carcinoma—What More is to Come?
Zachary A. Yochum, David A. Braun
Targeted Oncology (2025)
Closed Access
Impact of the ONCOBIOME network in cancer microbiome research
Laurence Zitvogel, Lisa Derosa, Bertrand Routy, et al.
Nature Medicine (2025)
Closed Access
Influence of the gut microbiota on immune cell interactions and cancer treatment
Chunxiao Liu, Lingfeng Fu, Yuxin Wang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
Mi Young Lim, Seungpyo Hong, Young‐Do Nam
Frontiers in Immunology (2025) Vol. 15
Open Access
Decoding the potential microbiome modulation strategies from bugs to drugs in pancreatic cancer: Insights from clinical trials
Yuning Wang, Wang Shuhang, Ning Li
Cancer Letters (2025), pp. 217465-217465
Closed Access
Clinical Applications of Microbiome in Renal Cell Carcinoma
Salim Elyas, Pedro Barata, Ulka N. Vaishampayan
European Urology Focus (2025)
Closed Access
Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma
Kevin Zarrabi, Ulka N. Vaishampayan, Pedro Barata
European Urology Focus (2025)
Closed Access
What Is the Role of Fecal Microbiota Transplantation in Immunotherapy Trials? Current Perspectives and Future Directions
Edmond Rafie, Miguel Zugman, Sumanta K. Pal, et al.
European Urology Focus (2025)
Closed Access
Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma
Isabella Portugal, Maria Alejandra Clavijo-Salomon
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Causal role of the gut microbiome in certain human diseases: a narrative review
Connor Prosty, Khaled Katergi, Jesse Papenburg, et al.
eGastroenterology (2024) Vol. 2, Iss. 3, pp. e100086-e100086
Open Access
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Sharon H. Choi, Yu‐Wei Chen, Justine Panian, et al.
The Oncologist (2024)
Open Access
Validation of urine p-cresol glucuronide as renal cell carcinoma non-invasive biomarker
Júlia Oto, Raquel Herranz, P Verger, et al.
Journal of Proteomics (2024) Vol. 311, pp. 105357-105357
Closed Access
Microbiome-based Therapeutics: Cutting-edge Innovation
Mitsuru Komeya, Scott D. Lundy
European Urology Focus (2024)
Closed Access
Microbiome-based Therapeutics: Cutting-edge Innovation or Perpetual Promise?
David J. McConkey, Jennifer J. Barb, Armine K. Smith, et al.
European Urology Focus (2024)
Closed Access
Page 1

Scroll to top